entity

Poly(ADP-ribose) polymerase / DNA damage repair

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Poly(ADP-ribose) polymerase / DNA damage repair: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections
1Hypotheses
1Analyses
0Outgoing
1Incoming

Outgoing (0)

TargetRelationTypeStr
No outgoing edges

Incoming (1)

SourceRelationTypeStr
PARP1participates_ingene0.50

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
PARP1 Inhibition Therapy 0.575 neurodegeneration TDP-43 phase separation therapeutics for

Mentioning Analyses (1)

Scientific analyses that reference this entity

TDP-43 phase separation therapeutics for ALS-FTD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.575

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Transcription-replication conflicts underlie sensitivity to PARP inhibitors. [PMID:38509368] Petropoulos M, Karamichali A, Rossetti G Nature 2024 1
PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in o [PMID:38778348] Liu C, Li J, Xu F, Chen L, Ni M, Wu J, Z Mol Cancer 2024 1
USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity. [PMID:39536107] Nespolo A, Stefenatti L, Pellarin I, Gam Sci Adv 2024 1
NAD(+) rescues aging-induced blood-brain barrier damage via the CX43-PARP1 axis. [PMID:37683629] Zhan R, Meng X, Tian D, Xu J, Cui H, Yan Neuron 2023 1
Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. [PMID:30356214] Liu H, Zhang H, Wu X, Ma D, Wu J, Wang L Nature 2018 1
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1- [PMID:41499130] Herzog SK, Stevens JH, Gu G, Grimm SL, C Cancer Res 2026 0
Design, synthesis and biological evaluation of novel pyrrolo[1,2-b]pyridazin-2(1 [PMID:41672027] He Q, He J, Huan X, Song S, Zhang X et a Eur J Med Chem 2026 0
Molecular and Antiangiogenic Effects of Paclitaxel-Loaded Nanoparticles: Influen [PMID:41790974] Passos JS, de Melo GB, Salata GC, Machad Mol Pharm 2026 0
Replicative gaps in DNA damage tolerance, genome instability, and cancer therapy [PMID:41864203] Falbo L, Costanzo V Mol Cell 2026 0
Versatile and sensitive detection of mono- and poly(ADP-ribosyl)ation reveals XR [PMID:41922367] Dauben H, Mihaljević M, Kolvenbach A, Pa Nat Commun 2026 0
Differential proteomic responses to short-term heat stress in Vechur and crossbr [PMID:41931203] Anisha JP, Shynu M, Radhika G, Beena V, Tropical animal health and pro 2026 0
Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 in [PMID:41931484] Chapman IG, Wu X, Veuger S, Jowsey PA PLoS One 2026 0
Effective oral countermeasures against ionizing radiation-induced damage without [PMID:41946301] López-Blanch R, Oriol-Caballo M, Salvado Biomed Pharmacother 2026 0
Hepatic GAL1 deficiency alleviates steatosis via WWP2-mediated PARP1 degradation [PMID:41951010] Li Y, Li R, Wang P, Xu J, Zhang C et al. Biochim Biophys Acta Mol Basis 2026 0
Targeting Poly (ADP-Ribose) Polymerase-1 for the Treatment of Neurodegenerative [PMID:41178110] Polk S, Rassaeikashuk M, Thilagavathi R, Chemical biology & drug design 2025 0
Increased nucleotide metabolism alleviates Alzheimer's disease pathology. [PMID:41102145] ["Yu Y", "Miller M", "Huang A", "Tan B", Cell death & disease 2025 0
Roles and therapeutic potential of PARP-1 in neurodegenerative diseases. [PMID:41022359] ["Liu C", "Lai F", "Zhang T", "Mao K", " Biochemical pharmacology 2025 0
Tipping the PARylation scale: Dysregulation of PAR signaling in Huntington and n [PMID:40905723] Peng C, Maiuri T, Truant R Journal of Huntington's diseas 2025 0
Targeting KCNN4 channels modulates microglial activation and apoptosis in a PD-r [PMID:40913912] ["Hung H", "Li I", "Lin Y", "Yeh T", "Ng Biomedicine & pharmacotherapy 2025 0
Clinical approaches to overcome PARP inhibitor resistance. [PMID:40442774] ["Zou Y", "Zhang H", "Chen P", "Tang J", Molecular cancer 2025 0